ERBB2 and neoplasm: Features extracted from the tumor immune microenvironment and clinical data were employed to train machine learning models for the precise prediction of the response to neoadjuvant CT (AUC for HER2+ patients = 0.8975; AUC for TNBC patients = 0.7674), demonstrating superior algorithm performance compared to pathologists [120].